Sten Scheibye, Ph.D., is the Chairman of the BII board of directors under the three-year establishment phase. He was a member of the Novo Nordisk Foundation’s board of directors and Chairman of the board from 2013 to 2018. He holds a MSc in Chemistry and Physics from 1978 and a Ph.D. in Organic Chemistry from 1981, both from the University of Aarhus, Denmark. In 1983, he obtained a BComm from Copenhagen Business School. From 1995 to 2008, Sten Scheibye was President and CEO of Coloplast A/S, Denmark. Before joining Coloplast in 1993, he served as Senior Vice President, Sales & Marketing in Leo Pharma A/S, Denmark. He joined this company in 1981. Sten Scheibye is Chairman of the Danish Industry Foundation, RMIG, Knud Højgaards Foundation, Højgaard Ejendomme A/S and Healthcare DENMARK.

Bo Ahrén is the vice-chair of the BII board of directors under the three-year establishment phase. He was a member of the Novo Nordisk Foundation’s board of directors from 2005 to 2017. Bo Ahrén is pro-vice-chancellor of external engagement and professor of clinical metabolic research at the Department of Clinical Sciences in Lund. He conducts research on diabetes and has been involved in developing new drugs to treat type 2 diabetes. He has previously been chief of medicine at Region Skåne and head of the research clinic at Skåne University Hospital in Lund.

Hans Schambye is a biotech executive with a background in corporate strategy, financing and management, drug discovery and development. He has an extensive biological understanding of diseases, experience with pharmaceutical business development and market analysis for drug products and portfolio management.

Martin Bonde has + 25 years of international experience from the biotech industry and has held several leadership positions as CEO for e.g Vaccibody AS,  Epitherapeutics Aps, Natimmune A/S, Combio A/S, Torsana Biosensor A/S, and Ostemeter Biotech A/S.

Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, Endostim, GTX Medical, SNIPR Biome, STipe Therapeutics, Themis and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), and an external director at GlaxoSmithKline’s Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences. She currently serves as the Spokesperson for the Board of the German PE and VC Association (BVK).

Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics, F-star, and Jenavalve, and served on several Boards, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners, and built her extensive network in the global healthcare industry during her tenure at McKinsey. In the 90s, Regina gained initial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.

Robert G. Urban has over 25 years of international experience in the healthcare industry. In 2018, Robert retired from Johnson and Johnson as the Global Head of Johnson & Johnson Innovation, LLC. Prior to joining J&J, Robert was the founding Executive Director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). He was previously the CEO of Acretia Inc, he has also held founding and executive positions at ZYCOS Inc and Pangaea Pharmaceuticals. Robert has served on the Board of diverse companies and not-for-profit organizations.

Senior management professional with +25 years of R&D and business development experience from the bacteria and enzymes industry. He is a co-inventor on a number of patents as well as publisher of several scientific papers and publications with WWF, WEF and the German Bioeconomy council.